Genetic markers indicative of a cancer patient response to trastuzumab (herceptin)

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9677139
APP PUB NO 20120328607A1
SERIAL NO

13491359

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to the fields of therapeutics and identifying candidates for therapy, in particular to a method of identifying candidates for trastuzumab (Herceptin®) therapy in a patient presenting with breast cancer based on the presence or absence of specific genetic markers in a tumor sample from said patient.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
COLD SPRING HARBOR LABORATORYP O BOX 100 COLD SPRING HARBOR NY 11724

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hicks, James Huntington, US 31 459
Krasnitz, Alexander Huntington, US 4 56

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 13, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 13, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00